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An aged Barbary ape (Macaca sylvanus) at the Toronto
Zoo became infected with naturally acquired West Nile virus
encephalitis that caused neurologic signs, which, associated
with other medical problems, led to euthanasia. The diagnosis
was based on immunohistochemical assay of brain lesions,
reverse transcriptase–polymerase chain reaction, and virus
isolation.
W
est Nile virus (WNV) is an arbovirus in the
Flaviviridae family, which may cause inapparent
infection, mild febrile illness, meningitis, encephalitis, and
death in birds and mammals, including humans (1–3).
Wild birds are the principal reservoirs of WNV, and mos-
quitoes, especially Culex species, are the primary vectors
(4). WNV has caused several epidemics in the last 10 years
(3). In 1999, WNV was detected in New York City (5). In
Canada, WNV was first documented in August 2001 (6).
We provide the first report of disease due to naturally
acquired infection with WNV in a nonhuman primate.
On August 17, 2002, symptoms of acute neurologic dis-
ease were observed in a 25-year-old male, 10.5 kg,
Barbary macaque (Macaca sylvanus) at the Toronto Zoo.
The animal behaved normally when observed by zookeep-
ers the day before. It was housed with 10 other Barbary
macaques in an outdoor exhibit with access to indoor hous-
ing. The animal exhibited clinical signs of neurologic
involvement including ataxia, shaking, a drooping lower
lip, excessive salivation, decreased responsiveness to sur-
roundings, and nystagmus. The animal was anesthetized
for further evaluation and a limited additional neurologic
examination. Minor deviations were noted in hematology
and serum biochemistry ranges. Because of severe chronic
arthritis and the marked neurologic signs, the animal was
euthanized and postmortem examination was performed.
The examination showed moderate gingivitis, general-
ized severe muscle atrophy, and severe bilateral femorotib-
ial osteoarthritis. Brain and meninges were normal on
gross examination. Tissues were collected from all major
organs and frozen at –20°C. Additional samples from all
major organs were fixed in 10% buffered formalin. The
fixed brain was cut transversely from the rostral end to the
spinal cord, each segment being 0.5 cm to 1.0 cm thick.
Representative samples were taken from cortex, thalamus,
hippocampus, midbrain, colliculi, pons, obex, medulla
oblongata, and cerebellum. The tissue samples were subse-
quently trimmed and processed for routine histopathology.
West Nile Virus immunohistochemistry was prepared by
using rabbit polyclonal anti-WNV antiserum (Hana
Weingartl, National Center for Foreign Animal Disease,
Canadian Food Inspection Agency). Goat anti-rabbit
immunoglobulin conjugated to a horseradish peroxidase
(HRP)-labeled polymer (EnVision HRP, DAKO
Cytomation, Inc., Missisauga, Ontario, Canada) was used
as the secondary antibody. Nova Red (Vector Laboratories
Canada Inc., Burlington, Ontario) was used as chromogen,
and tissues were counterstained with Harris hematoxylin
(Fisher Scientific, Toronto, Ontario). For negative con-
trols, nonimmune rabbit serum was substituted for WNV
antiserum. 
Microscopically, a severe nonsuppurative meningoen-
cephalitis was characterized by generalized gliosis, scat-
tered glial nodules, and perivascular lymphoplasmacytic
cuffing. The distribution and severity of lesions were bilat-
erally symmetrical. The brainstem, pons, colliculi, and
cerebellum had the most extensive lesions, the anterior
cortex and midbrain were moderately affected, and the
posterior cortex mildly affected. Moderate mononuclear
infiltrates and edema were present throughout the
meninges, most severely over the cerebellum. 
Immunohistochemistry for WNV was positive. WNV
antigen was present in cerebellar Purkinje cells, neurons,
and glial cells within or adjacent to sites of inflammation in
the cerebellum, midbrain, and hypothalamus (Figure 1). A
few individual glial cells in the cerebral cortex were sparse-
ly stained (Figure 2). Viral antigen was not evident in liver,
lymph node, lung, or kidney tissues. Other histopathologic
findings included generalized moderate hepatocellular atro-
phy and focal to diffuse aggregates of lymphocytes, plasma
cells, and macrophages, some of which had centers of
caseous necrosis, in the renal interstitium.
WNVin brain tissue was also documented by the detec-
tion of viral genome by using real-time reverse transcrip-
tase–polymerase chain reaction (RT-PCR) and by virus
isolation. Extracted RNAwas added to TaqMan PCR reac-
tion (PE Applied Biosystems, Foster City, CA) mixtures
containing primers and probes specific for the WNV
(North American genotype) envelope gene and the 3′ non-
translated region (7). Viral RNAwas amplified by using an
ABI 7700 Sequence detector. 
Diluted brain homogenates were used to infect mono-
layers of Vero cells at 80% confluence. Viral cytopathologic
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tion was confirmed by immunofluorescence using chicken
anti-WNV polyclonal sera and one-step RT-PCR of infect-
ed tissue culture supernatants.
The serum sample was positive for WNV on hemagglu-
tination inhibition (HI) assays (8) with a low titer (1:40).
The serum sample was also tested with some of the WNV
enzyme linked immunosorbent assay (ELISA) developed
for humans. The Centers for Disease Control and
Prevention (CDC) immunoglobulin (Ig) M ELISA and the
PanBio (Columbia, MD) IgM ELISA produced equivocal
results and the PanBio IgG ELISA results were negative.
Thirty-three primates in outdoor exhibits at the zoo
were tested for WNV. Serum samples, taken in late
December 2002 or spring 2003, were tested for antibodies
to WNV by HI assay, and subsequently by plaque reduc-
tion virus neutralization (PRVN) if the HI test was positive
(8). One of seven olive baboons (Papio cynocephalus anu-
bis) had a titer on HI (1:320) and on PRVN (1:80). Two of
16 Japanese macaques (Macaca fuscata) had titers on HI
(1:160 and 1:20), but only the first of these had a titer on
PRVN test (1:40). None of the remaining 10 Barbary apes
had serologic reactions. 
Clinical signs in our study were similar to those
observed in experimentally infected cynomolgus
macaques (Macaca fascicularis) and rhesus macaques
(Macaca mulatta) injected intracerebrally with the Egypt-
101 strain of WNV, and in rhesus macaques injected
intrathalamically by using 10 different strains and mutants
of WNV (9,10). Neurologic signs increased for several
days and ptosis, paresis of the extremities and sphincters,
adynamia, and marked hypothermia were observed. If the
animals did not die, their illness went into remission over
the following 2 weeks. 
The histologic lesions in our studies were similar in
morphology findings and distribution to those described in
experimentally infected macaques (9,10) and in severe
cases in humans (11,12). A number of strains of WNV are
capable of long-term persistence in nonhuman primates
(10). In these animals the pathogenicity or neuroinvasive-
ness of the virus decreased with time. Some animals car-
ried the virus for as long as 5 1/2 months, suggesting that
primates might be carriers of WNV in foci of infection.
These findings should be taken into account when using
these animals as sources for cell cultures. A persistently
infected nonhuman primate is unlikely to contribute to the
WNV-mosquito cycle. Whether a persistently-infected
nonhuman primate could be a source of infection for con-
specific cage mates or people through bite wounds and
scratches is speculative. Persistent infection with WNV
has not been reported for other mammals.
The Barbary macaque in this case was probably
immunocompromised to some degree, as it was aged and
in poor physical condition; however, B-dependent splenic
follicles were not atrophic. Hepatocellular and pancreatic
atrophy, and poor physical condition, indicated reduced
food intake. In humans, increasing age is considered a sig-
nificant predisposing factor for more severe clinical dis-
ease in WNV infection (13).P P
The prognosis for clinically affected nonhuman pri-
mates is difficult to predict based on one affected animal.
However, a wide variance occurred in responses in exper-
imentally infected macaques (10). The factors, except
increased age, that predispose people to clinical disease are
unknown (13). Resolution of the lesions is believed to be
complete in human survivors of WNV meningoencephali-
tis, but for reasons poorly understood, permanent neuro-
logic sequelae occur in some persons (3). 
Since most cases in humans are mild or asymptomatic,
such is probably the case in nonhuman primates, i.e., the
clinically normal seropositives at the zoo. Infection may be
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Figure 1. Staining of West Nile virus antigen in the cytoplasm of a
Purkinje cell in the cerebellum. Immunohistochemistry.  Magnifi-
cation x40.
Figure 2. Staining of West Nile virus antigen in a glial nodule in the
brainstem. Immunohistochemistry.   Magnification x20.prevalent but subclinical in nonhuman primates housed
outdoors, or with access to outdoor holdings, in disease-
endemic areas (14). Keeping the animals inside, especially
infants and old adults, may be important when the virus is
prevalent in surrounding mosquito populations or during
periods of peak mosquito activity. 
The Barbary ape was the first clinical case of WNV
infection in any species recognized at the Toronto Zoo
where WNV subsequently caused disease in a variety of
avian species. WNV infection should be included as a dif-
ferential diagnosis in all cases of muscle weakness and
neurologic signs in nonhuman primates housed with out-
door access in WNV-endemic areas during the mosquito
season. Virologic or serologic confirmation should be
obtained in all suspected cases of WNV in nonhuman pri-
mates. Since the viremic stage is short, exposure is more
reliably confirmed with paired serum samples demon-
strating an increase in antibody to WNV (14), usually by
HI, confirmed by plaque reduction virus neutralization.
Neither of these tests are “species limited” in that they can
be used in animals for which specific test reagents are not
available (3,15). However, plaque reduction virus neutral-
ization requires biosafety-level 3 facilities. Notably, IgM
ELISA tests used in humans gave equivocal or negative
results in this case. Laboratory findings and diagnostic
techniques used in people are found in several articles (3,
15). 
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